All the news Showing 6 of 26 articles from: Finance, funding & health economicsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Low uptake of HCV treatment in England will lead to substantial disease burden by 2035 Michael Carter / 24 June 2014 Only 3% of people with chronic hepatitis C virus (HCV) are treated for their infection each year in England, according to research published in the Journal of Hepatology. The current uptake of ... Report highlights major failings in UK response to hepatitis C Michael Carter / 07 May 2013 The UK needs to “be doing so much more” in response to hepatitis C, according to a new report. Supported by a consortium of leading hepatitis C charities, Confronting the silent epidemic: a ... Early hepatitis C treatment may not be cost-saving in France - but early diagnosis will save money Keith Alcorn / 07 May 2013 Treating hepatitis C earlier than recommended by current French and European treatment guidelines, before the development of severe liver fibrosis, may not result in substantial cost savings even if the price of direct-acting ... Study shows the high human and economic burden of HCV infection in Europe Michael Carter / 24 April 2013 A large European study has provided valuable insights into the high economic and human costs of infection with hepatitis C virus (HCV). Published in BMC Gastroenterology, the research showed that HCV infection was ... Which patients should be prioritised for new hepatitis C treatments? Rob Camp / 23 November 2012 Younger patients with advanced liver disease caused by hepatitis C should be prioritised for treatment with newly licensed directly acting antivirals to achieve the biggest reductions in ill health and hospitalisation, according to ... Hepatitis C protease inhibitor therapy cost-effective in some circumstances Michael Carter / 21 February 2012 First-line hepatitis C therapy which includes a protease inhibitor can be cost-effective, investigators show in the Annals of Internal Medicine. The study showed that a triple combination of drugs, including the cheaper ... ← Prev123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive